The Pfizer-BioNTech vaccine continued to be highly effective against COVID-19 after six months, suggest long-term results from a trial.

Follow-up data from the final-stage trial involving 46,307 individuals suggests that the vaccine was 91.3% effective in preventing symptomatic cases starting one week after the second dose until about six months. In the U.S. alone, the vaccine had an efficacy rate of 92.6%. The companies also provided some of the initial data on how the vaccine might handle the B.1.351 variant that was first identified in South Africa. Nine of the 800 participants in that country contracted COVID-19, including six infected with B.1.351 variant. However, all of them were in the placebo group, thus suggesting that the vaccine was effective against the variant… (NDTV – Bloomberg, April 2, 2021)